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Abstract
Introduction: Xeroderma pigmentosa (XP) is a hereditary disease characterized by deficient repair of DNA damage 
that occurred on exposure of the skin to ultraviolet irradiation. The affected children have a propensity to develop 
multiple skin cancers mainly in the face and eventually die before the age of 20.
Hypothesis: Allograft replacement of facial skin by a healthy skin from normal person might decrease the incidence of 
skin cancer development, the number of surgical procedures, and eventually might improve the survival of these 
miserable patients.
Methods: As Cadaveric organs are unavailable in our country. After approval from the ethical committee, confirmed 
agreement of the donor and the patient's guardian, a radial forearm free flap was transplanted from an ABO 
compatible mother to her 5 year old daughter with XP. The mother had an older daughter died from the same disease 
at the age of 14. The flap replaced skin of the hemi face that developed precancerous lesions. The girl was kept on 
adjusted doses of immunosuppressive drugs.
Results: The flap survived, wounds healed uneventfully. The flap developed a reddish spot one and half month 
following transplant where baseline skin biopsy was taken. In the fifth months the girl presented with bad non 
salvageable rejection that ended up loosing the flap. On long term follow up, the girl started to develop skin lesion on 
the virgin half of the face. Our early cosmetic result replacing half of the facial skin was very promising. In addition the 
girl did not develop skin lesions in the operated site.
Conclusion: Our early cosmetic result was very promising. In addition to this, the girl did not develop skin lesions in 
the operated side of the face
Introduction
Xeroderma pigmentosa (XP) is an autosomal recessive
genetic disorder that makes the DNA of the skin unable
to repair the continuous damage inflicted on it by the
Ultra Violet (UV) rays present in sun rays [1]. A dominant
form of XP was described in a Scottish girl; these patients
have a mild clinical course [2]. The disease is character-
ized by photosensitivity, pigmentary changes, premature
skin ageing, neoplasia and abnormal DNA repair. Some
pa tients also ha ve neur ological com plica tions. Affect ed
individuals are 1000 times more prone to UV induced
skin cancer than unaffected ones and over 90% of affected
individuals will develop skin malignancy before the end
o f  t h e i r  s e c o n d  d e c a d e  [ 3 ] .  D e v e l o p m e n t  o f  m u l t i p l e
recurrent skin malignancy is the eventual outcome of this
DNA repair failure which world-wide kills two thirds of
the affected subjects before the age of 20. Death follows a
lengthy devastating illness for both the patient and his
family where malignant lesions can develop as early as the
third or fourth year [2]. During their life span they get
exposed to repeated surgical resection of newly-devel-
oped skin cancers. Surgical resection ranges from simple
excision and skin closure to heroic cranio-facial resection
and free flap reconstruction.
In a desperate attempt to prevent malignant transfor-
mation, affected individuals have to be kept away from
sun light through out there life. There is no definitive
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treatment to the disorder up to the moment. Current
interventions aim at preventing, or better say, delaying
the occurrence of malignancy using both medical and
surgical approaches, none of them is truly successful.
Replacement of the skin of the face represents one of the
approaches. It has been tried using autologous skin
grafts, but again skin grafts (that carries the same genetic
disorder) developed malignancy when transferred to the
face.
Hypothesis: If the skin of the face can be replaced by
skin from a healthy individual (not carrying the genetic
disorder), it should not develop malignancy when
exposed to the UV rays. This might decrease the inci-
dence of skin cancer development, the number of surgical
procedures, improve the quality of life and eventually the
survival of those miserable patients.
Materials and Methods
As cadaveric organs are unavailable in our country, a sen-
sate radial forearm free-flap will be harvested from ABO
compatible and HLA typed living related donor. A three-
staged procedure was planned:
Stage one: Full thickness Excision of the skin of one side
of the face and replacing it immediately by a sensate free
vascularized fasciocutaneous radial forearm flap har-
vested from her healthy donor . Part of the face is to be
covered by split thickness graft again from the donor to
assess any difference in performance between the fascio-
cutaneous flap and split thickness grafts when used as
allograft to guide future procedures. The donor site is to
be closed by an auotologous partial thickness skin graft.
Stage two: Immune suppression and postoperative care.
Immunosuppressive regimen:
1- Corticosteroids:
• Methylprednisolone: 10 mg/kg/day, single daily 
dose was started 2 days pre-operative until day 3 
post-operative
• Methylprednisolone: 5 mg/kg/day, single daily 
dose from day 4-day 6 post-operative
• Prednisone 2 mg/kg/day divided in 3 daily doses 
started from day 7 and tapered gradually over the 
next 3 months and was discontinued on day 90 
post-operative
• Monitoring for steroids side effects was carried 
out by 6 hourly measurement of blood pressure 
while the patient was hospitalized and every visit 
thereafter. Blood sugar was also closely monitored 
during hospital stay.
2- Cyclosporine (Neoral): was started at a dose of 5 
mg/kg/day 2 days before surgery and monitored 
thereafter by trough level around 150 ng/ml. Moni-
toring of trough level was done twice weekly at the 
start until the desired level was achieved and monthly 
thereafter. Kidney functions were monitored twice 
weekly during hospitalization and on every subse-
quent visit.
3- Mycofenolate mofetil (Cellcept): was started on day 
1 post-operative, 250 mg capsule was given twice per 
day. Patient was monitored for myelosuppression by 
twice weekly complete blood counts in the first 3 
weeks and monthly thereafter.
Stage three: after ensuring successful technical and
immunologic outcome, the rest of the face is to be sub-
jected again to excision of the native skin and coverage by
either tissue expansion of the transplanted skin or by
another transplant.
Should any unfavorable outcome be encountered as
regards the viability of the transplanted skin, it is to be
replaced by autologous split thickness graft which is the
eventual end point for these patients if left untreated until
development of malignancy.
Consent
After approval from the ethical committee of the
National Cancer Institute. Fully informed counseled con-
sent was taken from the patient's parents. This included
discussion of alternative treatment options, an emphasis
about the fact that the procedure is a new procedure for
that kind of pathology, possible complications of the pro-
posed procedure, the need for postoperative immune
suppression and its potential complications. 'Written
informed consent was obtained from the patient for pub-
lication of this case report and accompanying images. A
copy of the written consent is available for review by the
Editor-in-Chief of this journal. We performed the first
case of living-related facial skin transplant from a mother
to her 5-year old daughter with XP who started develop-
ment of precancerous skin lesion. The mother had an
older daughter who died from the same disease at the age
of 14. Surgery was done on May 28, 2008.
Postoperative management
The patient was isolated in a surgical ICU, the viability of
the transplanted skin was monitored by visual observa-
tion and palpation of temperature as well as by hand-held
Doppler
Results
Surgical pathology of the excised skin showed foci of
marked dysplasia and carcinoma in situ lesions. The flap
survived the early postoperative period. The wounds
healed uneventfully and the patient was discharged on a
weekly outpatient visit for follow up (Figures 1, 2, 3).
Immune suppression was done as planned as given in
detail in the methods portion.
One and half month following the transplant: The girl
developed a reddish spot on the flap where a baseline skin
biopsy was taken that revealed minimal immunologicAmin et al. Head & Neck Oncology 2010, 2:18
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reaction, and this spot faded away spontaneously (Figures
4, 5, 6).
Two months post transplant: The girl was doing fine,
apart from hirsutism form the cyclosporine. The girl has
missed the follow up for 3 weeks before this visit and pre-
sented, in the fifth month, with clinical evidence of graft
rejection. The trough level of Cyclosporine at presenta-
tion was below the target level. Interestingly enough, the
skin graft was not affected with the rejection process. A
trial of salvaging the flap by corticosteroids and manipu-
lating the immunosuppressants was unsuccessful, so the
flap was removed, immunosuppressants were discontin-
ued and the face was left to granulate (Figures 7, 8, 9, 10).
For obvious reasons, the third stage of the planned proce-
dure (tissue expansion) was aborted. By the 10th month
Postoperative, the patient started to develop malignant
lesions in the non-operated side of her face (Figure 11).
The donor site in the mother that was closed by a partial
thickness skin graft healed uneventfully as well (Figure
12).
Discussion
Xeroderma pigmentosa is a devastating morbidity for the
patient and the family as well as the caring medical team.
The author's previous experience with this lethal devasta-
tion inspired executing the idea with any prospect of suc-
Figure 1 Early postoperative outcome front view with the area 
covered by split thickness skin graft defined by arrows.
Figure 2 Side view showing the healthy radial forearm flap.
Figure 3 Cosmetic outcome after the flap has remodeled to the 
face of the patient.
Figure 4 Spots marked by an arrow denoted early rejection.Amin et al. Head & Neck Oncology 2010, 2:18
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cess. The mother having witnessed the life and death of
her previously affected offspring, unsurprisingly,
accepted with enthusiasm donating her skin. Attempts to
resurface their faces have been tried using autologous
skin that ended up developing malignant lesions as it still
carries the same genetic defect. To the best of the author's
knowledge, this is the first attempt of allotransplantation
for patients with Xeroderma pigmantosa.
Figure 5 Base line skin biopsy showing lymphocytic infiltration.
Figure 6 Spots have faded away.
Figure 7 Irreversible graft rejection.
Figure 8 complete healing by spontaneous granulation 5 
months after removal of the flap.Amin et al. Head & Neck Oncology 2010, 2:18
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There were two issues as regards timing in this proce-
dure. First, is whether to do the transplantation before or
after development of malignant lesion? Second, is
whether to do the skin expansion before or after trans-
plantation i.e. in the arm of the mother or in the face of
the patient? Prophylactic excision was chosen in this case
to avoid the use of immunosuppressants in the face of a
coexisting invasive malignancy. It might seem logical and
tempting to expand the skin in the arm of the mother to
allow harvesting ample tissue with the expander in a
rather convenient anatomical site. However, tissue expan-
sion was deferred to a post-transplant stage. The reason
was that transferring ample skin would have simply
m e a n t  e x c i s i o n  o f  a m p l e  f a c i a l  s k i n  a s  w e l l  f r o m  t h e
patient. Should removal of the graft prove to be necessary
Figure 9 18 months later showing the cosmetic outcome after 
healing with secondary intention following debridement of the 
rejected flap (front view).
Figure 10 Lateral view.
Figure 11 Ten months post transplant where the patient started 
to develop skin lesions in the contra lateral side (marked by an ar-
row). Worth noting that the side operated upon and left to heal by sec-
ondary intention did not develop any new lesions.
Figure 12 Late Postoperative follows up of the donor site in the 
mother's forearm; covered by a split thickness graft.Amin et al. Head & Neck Oncology 2010, 2:18
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for any reason; a large raw area would have resulted in
such a case.
The rationale behind the attempt was that the develop-
m e n t  o f  s k i n  m a l i g n a n c y  i s  a l m o s t  c e r t a i n  i n  t h e s e
patients. Standard treatment is excision and split thick-
ness grafting. Therefore, loosing the graft and resurfacing
by autologous split thickness graft is not too far from this
end point if the patient was left untreated. Immune sup-
pression in a patient well known to be prone to malig-
nancy was an issue of concern. Experience from long
t e r m  f o l l o w  u p  o f  r e n a l  t r a n s p l a n t  p a t i e n t s  p o i n t e d  t o
Immune suppression as a risk factor for developing
malignancy with an 18-fold rise in risk for developing
squamous carcinoma in these patients [4]. This was not
enough for the authors to abort the idea as xeroderma
pigmentosa patients, when left untreated, they systemati-
cally develop malignancy and usually die in the second
decade of life, so they simply can not be rendered "more
prone" to malignancy. They are already at the height of
susceptibility. Given this fact, the authors chose not to
loose the grip on the idea and they chose to see whether
this theoretical (but certainly relevant) risk will really set
in on clinical grounds or not, as this risk has not been
assessed clinically in this particular subset of patients. In
addition, hepatologists extended the indications for liver
transplantation to include some patients with hepatocel-
lular carcinoma. They do receive immunosuppressants in
the immediate postoperative period. Whether Immune
suppression accelerates the malignant process in this sub-
set of patients or not, reports are conflicting and it seems
that the best answer to this question is the answer given
Schwartz et al; "we do not know" [5].
We believe that the way out of this morbidity is either
prevention by genetic counseling and prenatal diagnosis
or by gene therapy for those whom it happened that they
are born with the defect. Genetic counseling and prenatal
diagnosis are currently available in clinical practice but
gene therapy is still investigational. Various methods of
correcting the defects in xeroderma pigmentosum have
been attempted in vitro and in animal studies using viral
vectors (adenoviruses and retroviruses) carrying the gene
replacement products. Ex vivo skin gene therapy, which
refers to grafting skin that has the genetic defect cor-
rected may be useful in xeroderma pigmentosum in the
future [6]. A new approach is to repair DNA damage after
UV exposure. This can be accomplished by delivery of a
DNA repair enzyme into the skin by means of specially-
engineered liposomes [7]. Employing this therapy over a
period of 1 year, Yarosh et al [8] demonstrated a reduc-
tion in the onset of actinic keratosis and Basal cell carci-
noma. Oral retinoids have been shown to decrease the
incidence of skin cancer in patients with xeroderma pig-
mentosum. This therapy is limited by dose-related irre-
versible calcification of ligaments and tendons.
As mentioned earlier, Skin excision and grafting by an
auto graft (total resurfacing) ended up by malignancy
developing in the grafted skin when it was transplanted to
sun exposed areas. Chemical peeling and dermabrasion
represent a less invasive method of resurfacing with
reports of a disease free period up to 4 years (free from
malignant lesions). However, protection from sun is still
mandatory after the procedure [9]. The attempt
described in this article can be looked at as an evolution
of the total resurfacing approach with the next step seems
to be cadaveric total face transplantation. Clinical
attempts of composite tissue allotransplantation have
been described between identical twins [10,11]. When
the donor is not an identical twin, these reconstructive
procedures for non life-threatening indications remain
rare due to adverse effects of the associated lifelong
immunosuppressive therapy [12]. Face transplantation is
emerging as a solution to traumatic events with the first
report of a dynamic hemi face transplant following a dog
bite performed in France [13]. There are three dissimilar-
ities, however, between the case performed in France and
this report. These are; the indication of the procedure,
the type of tissue transplanted and lastly the regimen of
immune suppression. The indication in our report was
prevention of malignancy while in the patient reported in
France the indication was reconstruction of a lower face
amputated by a dog bite. The graft transplanted in France
was a composite graft containing skin, muscles and
mucous membrane with their nerve and blood supply
harvested from a brain-dead lady in her forties. As men-
tioned earlier, ethical committees in our country have not
yet approved brain-dead patients as donors which made a
living-related donor the author's only option which con-
sequently dictated the type of tissue that can be har-
vested. As regards immune suppression regimen; the
author's choice of drugs (described earlier) in the current
case was, in part, influenced by the available fund allo-
cated for the attempt. This immunosuppressive regimen
was modified from the regimen used by members of the
same team who work in the living related liver transplan-
tation program at Cairo University. Because skin is a
mixed tissue that is liable to more rejection than the liver,
the regimen used a dose of steroids that was higher than
that used for liver transplant recipients and was even
started earlier pre-operatively. Also, a combination ther-
apy of cyclosporine and mycofenolate mofetil was used
from the start. Liver transplant recipients receive mono-
therapy with tacrolimus (after steroids are discontinued)
and mycofenolate is added as rescue therapy if the recipi-
ent experiences acute rejections.
At the time of this skin transplant for the xeroderma
pigmentosa case, m-TOR inhibitors (sirolimus and ever-
loimus) were unavailable; which is not the condition now.
During the last year they were used in liver transplantAmin et al. Head & Neck Oncology 2010, 2:18
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recipients who experience repeated acute rejections not
controlled by proper doses of tacrolimus. The pediatric
hepatologists in the liver transplant team have also used
sirolimus in one case of chronic rejection (a rare condi-
tion) in a child and chronic rejection was successfully
controlled.
In the case performed in France, the Immunosuppres-
sive treatment was with thymoglobulin, tacrolimus,
mycophenolate mofetil, and prednisone. Two infusions of
donor bone-marrow cells were given. They described 2
episodes of rejection in 18 months follow up that were
reversed [14]. Another case was reported from China
were, in 2006, Guo et al performed a partial face trans-
plant to reconstruct a face of a man who sustained a bear
bite. They used Quadraple immunomodulatory therapy
containing tacrolimus, mycophenolate mofetil, corticos-
teroids, and humanized IL-2 receptor monoclonal anti-
body, and in two years follow up, they reported 3
episodes of rejection controlled by immune suppressive
therapy adjustmen [15]. Finally, a report of near total face
transplantation came from Cleveland in December, 2008.
The patient was a lady who sustained a shotgun [16].
Conclusion
Although we cannot comment on long term results due
to graft rejection, our early cosmetic result was very
promising. In addition to this, the girl did not develop
skin lesions in the operated site but developed one in the
virgin hemi-face. We believe that if we succeeded to high-
light the problem of these kids and ignite more research
in this direction, then we already achieved our goal.
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